Fintech PR
Piramal Pharma Limited Announces Consolidated Results for Q3 and 9M FY2024
MUMBAI, India, Jan. 30, 2024 /PRNewswire/ — Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceuticals company, today announced its standalone and consolidated results for the Third Quarter (Q3) and Nine Months (9M) ended 31st December 2023.
Consolidated Financial Highlights |
||||||
(In INR Crores) |
||||||
Particulars |
Q3 FY24 |
Q3 FY23 |
YoY Growth |
9M FY24 |
9M FY23 |
YoY Growth |
Revenue from Operations |
1,959 |
1,716 |
14 % |
5,619 |
4,918 |
14 % |
CDMO |
1,134 |
1,010 |
12 % |
3,101 |
2,720 |
14 % |
Complex Hospital Generic (CHG) |
576 |
514 |
12 % |
1,782 |
1,584 |
13 % |
India Consumer Healthcare (ICH) |
252 |
226 |
12 % |
747 |
664 |
13 % |
EBITDA |
330 |
170 |
94 % |
815 |
478# |
71 % |
EBITDA Margin |
17 % |
10 % |
15 % |
10 % |
||
PAT (after exceptional item) |
10 |
(90) |
NA |
(83) |
(237) |
NA |
PAT (before exceptional item) * |
35 |
(90) |
NA |
(59) |
(231) |
NA |
(In INR Crores) |
||||||
# 9M FY2023 EBITDA had one-time inventory margin impact of INR 68 Crores * Q3 FY24 Exceptional item of Rs.32 Crores is related to non-recurring charges towards product recall triggered by our third-party supplier
|
Key Highlights for Q3 and 9M FY2024
- Revenue from Operations grew by 14% YoY both in Q3FY24 and 9MFY24, driven by double digit growth across all the three businesses
- EBITDA grew by 94% YoY and 71% YoY in Q3FY24 and 9MFY24 respectively, primarily driven by operating leverage, reduction in raw material cost & energy prices, cost optimization, and operational excellence initiatives
- Net Debt / EBITDA ratio has improved over the last three quarters on account of healthy growth in EBITDA and repayment of debt from the proceeds of the recently concluded Rights Issue
- Sustainability – Taken a target to reduce Scope 1 and Scope 2 emissions by 42% by FY30 (with baseline of FY22), which is in accordance with 1.50 C trajectory suggested by SBTi. Further we have also taken a target to reduce Scope 3 emissions by 25% by FY30 (with baseline of FY22)
Nandini Piramal, Chairperson, Piramal Pharma Limited said, “We continue to build on our improved performance in FY24 with 14% YoY revenue growth in Q3 along with a significant improvement in EBITDA margin. Our CDMO business is delivering healthy growth with robust order inflows, especially for differentiated offerings and innovation related work. Our Inhalation Anesthesia portfolio is registering good volume growth in our key market of US and is also seeing increasing traction in ROW markets. Our India Consumer Healthcare business is delivering steady growth driven by our power brands and contribution from new product launches.
On the sustainability front, we have taken significant reduction targets for our Scope 1, 2 and 3 GHG emissions by FY2030. We are also working on multiple initiatives in the areas of water conservation, responsible waste disposal, gender diversity, employee safety, sustainable supply chain and community development.
We look forward to continuing our momentum in Q4 and end the financial year on a positive note.”
Key Business Highlights for Q3FY24 and 9MFY2
Contract Development and Manufacturing Organization (CDMO):
- Continued momentum with significant YoY growth in new orders* in 9M FY2024 vs 9M FY2023, more specifically in commercial manufacturing of on-patent molecules
- Recent order inflows have had higher quotient of innovation related work with good demand for our differentiated offerings
- During the quarter we received our first integrated anti-body drug conjugate (ADC) order involving monoclonal antibodies. Three sites involved – Lexington, Grangemouth and Yapan
- Continue to see improvement in profitability of our CDMO business driven by revenue growth, favorable revenue mix, normalization of raw material cost and cost optimization initiatives
- MHRA (UK) inspection of the newly commissioned multipurpose state-of-the-art ADC manufacturing facility at Grangemouth is scheduled for February 2024
- Maintained our quality track record – All our recently audited facilities by the US FDA have an EIR. Also, successfully closed over 140 customer audits in 9M FY2024
- Key challenges include partial recovery in biotech funding environment and clinical / regulatory attrition at customer end
Complex Hospital Generics (CHG):
- Volume growth in the inhalation anaesthesia portfolio in the US market, partly offset by lower market prices
- Increasing traction in our inhalation anaesthesia portfolio in the non-US markets
- Expanding our capacities to meeting growing demand of inhalation anaesthesia products. Also focus on improving output through greater operating efficiencies
- Improvement in profitability during Q3 and 9M FY2024 mainly led by cost optimization initiatives, yield improvement and better product and market mix
- Launched 3 new injectable products in Q3 FY2024 in the US and Europe. Building a pipeline of 25 new products which are at various stages of development with current addressable market size of over $2bn
- Key challenges include geopolitical risk, adverse currency movement (presence in over 100 countries), price erosion / lower realizations due to higher competition, and third-party development and supply chain risk in the injectable portfolio
India Consumer Healthcare (ICH):
- YoY improvement in EBITDA margin in 9MFY24 driven by operating leverage
- 6 new products and 3 new SKUs launched during Q3 FY2024. Over 100 new products launched between FY21 to FY24
- Continued to invest in media and trade spends to drive growth in power brands. Promotional spends during 9M FY2024 was at 13% of ICH revenue
- Power Brands – Littles, Lacto Calamine, Polycrol, Tetmosol and I-range, grew by 12% YoY in 9MFY24 and contributed to 41% of ICH sales
- E-commerce grew at about 17% YoY in Q3 FY2024, contributing 16% to ICH revenue. Presence across 20+ e-commerce platforms including own direct-to-customer website -Wellify.in
*New development and commercial orders. These are over and above the existing multi-year manufacturing relationships
Consolidated Profit and Loss Statement |
||||||||
(In INR Crores) Reported Financials |
||||||||
Particulars |
Quarterly |
Nine Months |
||||||
Q3FY24 |
Q3FY23 |
YoY Change |
Q2FY24 |
QoQ Change |
9MFY24 |
9MFY23 |
YoY Change |
|
Revenue from Operations |
1,959 |
1,716 |
14 % |
1,911 |
3 % |
5,619 |
4,918 |
14 % |
Other Income |
62 |
83 |
(25) % |
49 |
25 % |
149 |
201 |
(26) % |
Total Income |
2,020 |
1,799 |
12 % |
1,961 |
3 % |
5,768 |
5,119 |
13 % |
Material Cost |
675 |
625 |
8 % |
638 |
6 % |
1,940 |
1,864 |
4 % |
Employee Expenses |
524 |
492 |
6 % |
516 |
2 % |
1,535 |
1,423 |
8 % |
Other Expenses |
491 |
511 |
(4) % |
492 |
0 % |
1,478 |
1,355 |
9 % |
EBITDA |
330 |
170 |
94 % |
315 |
5 % |
815 |
478 |
71 % |
Interest Expenses |
106 |
95 |
12 % |
110 |
(4) % |
334 |
240 |
39 % |
Depreciation |
186 |
164 |
13 % |
185 |
1 % |
544 |
492 |
11 % |
Profit Before Tax |
38 |
(89) |
NA |
20 |
84 % |
(63) |
(255) |
NA |
Tax |
9 |
17 |
(44) % |
35 |
(73) % |
35 |
22 |
64 % |
Share of net profit of associates |
14 |
16 |
(10) % |
19 |
(27) % |
47 |
47 |
2 % |
Net Profit after Tax |
42 |
(90) |
NA |
5 |
744 % |
(51) |
(230) |
NA |
Exceptional item* |
(32) |
0 |
NA |
0 |
NA |
(32) |
(7) |
NA |
Net Profit after Tax after exceptional item |
10 |
(90) |
NA |
5 |
101 % |
(83) |
(237) |
NA |
Net Profit after Tax before exceptional item |
35 |
(90) |
NA |
5 |
594 % |
(59) |
(231) |
NA |
# 9M FY23 EBITDA had one-time inventory margin impact of Rs.68 Crore *Related to non-recurring charges towards product recall triggered by a third-party supplier
|
Q3 and 9M FY2024 Earnings Conference Call
Piramal Pharma Limited will be hosting a conference call for investors / analysts on 31st January 2024 from 5:00 PM to 5:45 PM (IST) to discuss its Q3 and 9M FY2024 Results.
The dial-in details for the call are as under:
Event |
Location & Time |
Telephone Number |
Conference call on |
India – 05:00 PM IST |
+91 22 6280 1461 / +91 22 7115 8320 (Primary Number) |
1 800 120 1221 (Toll free number) |
||
USA – 06:30 AM (Eastern Time – New York) |
Toll free number 18667462133 |
|
UK – 11:30 AM (London Time) |
Toll free number 08081011573 |
|
Singapore – 07:30 PM (Singapore Time) |
Toll free number 8001012045 |
|
Hong Kong – 07:30 PM (Hong Kong Time) |
Toll free number 800964448 |
|
Express Join with Diamond Pass™ |
Please use this link for prior registration to reduce wait time at the time of joining the call –https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=2184854&linkSecurityString=cc1d80a24 |
About Piramal Pharma Ltd:
Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter products. In addition, one of PPL’s associate companies, AbbVie Therapeutics India Private Limited (formerly Allergan India Pvt Ltd), a joint venture between Allergan (now part of AbbVie) and PPL, has emerged as one of the market leaders in the ophthalmology therapy area. Further, PPL has a minority investment in Yapan Bio Private Limited. In October 2020, PPL received a 20% strategic growth investment from the Carlyle Group.
For more information visit: www.piramaI.com/pharma I Twitter.
Logo – https://mma.prnewswire.com/media/1855206/Piramal_Pharma_Limited_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/piramal-pharma-limited-announces-consolidated-results-for-q3-and-9m-fy2024-302048384.html
Fintech PR
Ping An Wins Sixth Director of the Year Award and Inaugural Climate Governance Award from the Hong Kong Institute of Directors
HONG KONG and SHANGHAI, Nov. 29, 2024 /PRNewswire/ — Ping An Insurance (Group) Company of China, Ltd. (hereafter “Ping An” or the “Group”, HKEX: 2318/82318, SSE: 601318) received the Director of the Year Award and the Climate Governance Award for 2024 from the Hong Kong Institute of Directors (HKIoD) on November 28. This marks the sixth time Ping An’s Board of Directors has received the Director of the Year Award. Ping An is also the first recipient of the inaugural Climate Governance Award.
Since its establishment in 1988, Ping An has become one of the largest integrated financial, healthcare and senior care service providers in Mainland China. Ping An was nominated for the HKIoD awards for its diversified board of directors, dedicated to safeguarding the interests of the Company and all shareholders and promoting the Company’s long-term, stable development.
Mr. Ng Sing Yip, Independent Non-executive Director, accepted the awards on behalf of Ping An’s board. He said, “Ping An’s success as a world-leading integrated financial, healthcare and senior care service provider is closely linked to its high standards of corporate governance and the trust of our stakeholders.” The awards were also attended by Ms. Cai Fangfang, Executive Director and Senior Vice President, Ms. Cai Xun, Non-executive Director, Mr. Ng Kong Ping Albert, Independent Non-executive Director, Mr. Liew Fui Kiang, Independent Supervisor, and Mr. Hung Ka Hai Clement, Independent Supervisor, as representatives of the board and the Supervisory Committee.
Ping An’s Board of Directors will continue to lead the Company’s strategic planning, and participate in risk management, financial control, compliance, and internal control. The board will continue to enhance corporate governance and climate risk management capabilities, and grow value for stakeholders.
Ping An has long pursued a balanced and professional board structure. Ping An’s 15 directors possess professional expertise in insurance, banking, investment, accounting, law, management, and technology, with extensive industry and operational experience. Ping An has six independent non-executive directors, who account for 40% of the Board, exceeding the industry average. In 2023, the board completed 26 training sessions covering corporate governance, environmental and climate impact, and sustainable development. Since the Company’s listing, the board has conducted on-site inspections and reviews at grassroots level for 20 years, collecting opinions and suggestions from frontline employees and urging business units to continuously improve operational management.
Ping An’s Board of Directors focuses on providing foresight and guidance of the Company’s strategy for efficient implementation and high-quality business development. Under the leadership of the board, Ping An is promoting its “integrated finance + healthcare and senior care” strategy driven by technology. In the first three quarters of 2024, the Group’s operating profit attributable to shareholders of the parent company reached RMB113.82 billion, representing a year-on-year increase of 5.5%, and revenue reached RMB775.38 billion, a year-on-year increase of 10.0%. Three core businesses – life and health insurance, property and casualty insurance and banking – maintained growth, with their combined operating profit attributable to shareholders of the parent company reaching RMB119.65 billion, a year-on-year increase of 5.7%.
Ping An continues to strengthen integrated finance, shifting from cross-selling to comprehensive customer management. As of September 30, 2024, the Group had 240 million retail customers, a year-to-date increase of 3.8%. Customer retention continued to improve, with 25.1% of customers holding four or more contracts within the Group, and a retention rate of 98.0%. The healthcare and senior care strategy continued to yield results, with the value of Ping An’s differential advantages becoming more apparent. In the first three quarters of 2024, more than 19.5 million Ping An Life insurance customers used services in the healthcare and senior care ecosystem. Ping An’s innovative integrated “medical care, nursing, housing, and entertainment” model has established industry standards and ecosystems for senior care services. The services cover 75 cities across China, with more than 150,000 customers entitled to home-based senior care services.
Ping An’s Board of Directors oversees environmental, social and corporate governance (ESG) matters. It has built an efficient and collaborative long-term ESG governance mechanism, and promotes core practices such as climate governance and rural revitalization. Ping An pledges to achieve carbon neutrality across its operations by 2030, and has formulated short- and medium-term targets and roadmaps. In 2023, Ping An took the lead in launching China’s insurance industry’s first carbon account system covering all employees, recording each employee’s low-carbon office behavior, daily low-carbon behavior, and carbon emission data to support climate governance. Ping An also promotes green finance. In the first three quarters of 2024, Ping An’s green insurance premium income reached RMB37.34 billion.
Thanks to its outstanding performance in sustainable development, Ping An has received the highest ratings in multiple industry evaluations. Ping An has maintained an A rating in MSCI ESG Ratings for two consecutive years, ranking first in the multi-line insurance and brokerage industry in the Asia-Pacific region. It has been in S&P’s Sustainability Yearbook (China Edition) for two consecutive years, the only insurance company from Mainland China on the list. Ping An also has a “low risk” rating with a score of 17.0 in Morningstar Sustainalytics ESG Ratings and a B rating in CDP (Carbon Disclosure Project) Ratings, the highest ratings in China’s financial industry.
The HKIoD is Hong Kong’s premier organization representing professional directors, with more than 2,000 members from senior management of Hong Kong-based companies and listed companies worldwide. Its Director of the Year Awards evaluate companies’ performance in promoting development strategies, business strategies, and digital transformation at the board level. The Climate Governance Award, a newly launched award series in 2024, evaluates the performance of corporate boards in promoting sustainable development, climate governance and related information disclosure. The 2024 awards were co-organized by the Financial Services and the Treasury Bureau, the Securities and Futures Commission, and Hong Kong Exchanges and Clearing Limited.
Ping An will continue to adhere to responsible, high-standard corporate governance. Under the scientific and forward-looking guidance of the Board of Directors, Ping An will continue to deepen the “integrated finance + healthcare and senior care” strategy driven by technology, consolidate the advantages of integrated finance, promote its healthcare and senior care initiatives, advance digital transformation and pursue high-quality development. It is committed to creating greater value through stable growth for customers, employees, shareholders, and society.
About Ping An Group
Ping An Insurance (Group) Company of China, Ltd. (HKEx:2318 / 82318; SSE:601318) is one of the largest financial services companies in the world. It strives to become a world-leading provider of integrated finance, health and senior care services, Under the technology-driven “integrated finance + health and senior care” strategy, the Group provides professional “financial advisory, family doctor, and senior care concierge” services to its 240 million retail customers. Ping An advances intelligent digital transformation and employs technologies to improve financial businesses’ quality and efficiency and enhance risk management. The Group is listed on the stock exchanges in Hong Kong and Shanghai. As of the end of September 2024, Ping An had more than RMB12 trillion in total assets. The Group ranked 29th in the Forbes Global 2000 list in 2024 and 53rd in the Fortune Global 500 list in 2024.
For more information, please visit www.group.pingan.com and follow us on LinkedIn – PING AN.
Photo – https://mma.prnewswire.com/media/2569651/image.jpg
View original content:https://www.prnewswire.co.uk/news-releases/ping-an-wins-sixth-director-of-the-year-award-and-inaugural-climate-governance-award-from-the-hong-kong-institute-of-directors-302318512.html
Fintech PR
7th CIIE Successfully Wraps: Highlights by the Numbers
SHANGHAI, Nov. 28, 2024 /PRNewswire/ — The 7th China International Import Expo (CIIE) drew to a successful close on November 10th in Shanghai. While many intangible achievements and connections were made, this year’s data shows how the Expo achieved unprecedented success in global participation and business opportunities. Tentative deals totaled USD 80.01 billion, marking a 2 percent increase from the previous year.
Vibrant Participation from around the World
As a crucial platform for global collaboration, the 7th CIIE invited 77 countries and international organizations from five continents for the Comprehensive Country Exhibition. Participants incorporated unique cultures, national identities, and modern technology into booth designs, with an impressive lineup of over 200 captivating events hosted at the booths. A total of 3,496 companies from 129 countries and regions participated in the Enterprise & Business Exhibition, including 1,585 companies from 104 countries in the Belt and Road Initiative, 1,106 companies from 13 countries in the Regional Comprehensive Economic Partnership, and 132 exhibitors from 35 least developed countries.
Wide Range of Cutting-Edge Innovations and Debuts
Innovative achievements and diverse debuts have consistently been a major highlight from each edition of the expo. At the 7th CIIE, the Innovation Incubation Special Section showcased 360 innovative projects from 34 countries and regions, supporting the development of small and medium-sized enterprises (SMEs) and startups. In addition, multinational companies introduced 450 new products, services, and technologies, including over 100 global launches, 40 Asia premieres, and over 200 China debuts, unlocking momentum for new drivers of consumer demand.
International Perspectives and Collaborative Dialogues at the HQF
Serving as an important platform for international communication, the Hongqiao International Economic Forum (HQF) becomes a focal point of attention at each edition of the CIIE. Focusing on trending topics, the 7th HQF attracted over 8,600 registrations and convened more than 300 globally renowned experts and leaders in politics, business, and academia. The 7th HQF also released the World Openness Report 2024 alongside the World Openness Index, delivering a message of openness and fostering international cooperation.
The 7th China International Import Expo was undoubtedly a complete success, demonstrating its significant role as a stage for advancing global cooperation. With preparations for the 8th CIIE actively underway, the expo continues to expand opportunities for global trade and economic cooperation, warmly inviting countries and enterprises from abroad to join!
Visit CIIE official website for more information: https://www.ciie.org/zbh/en/?from=prnewswire
Contact: Ms. Cui Tel.: 0086-21-968888 Email: [email protected]
Photo – https://mma.prnewswire.com/media/2569264/image_5031553_31815944.jpg
Fintech PR
Europi Property Group AB (publ) successfully issues senior unsecured green bonds
STOCKHOLM, Nov. 28, 2024 /PRNewswire/ —
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR TO ANY PERSON LOCATED OR RESIDENT IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES TO DISTRIBUTE THIS ANNOUNCEMENT.
Europi Property Group AB (publ) (“Europi” or the “Company“) has successfully issued senior unsecured green bonds of EUR 50m under a framework of up to EUR 100m and a tenor of three years (the “Green Bonds“). The Green Bonds have a floating interest of 3M Euribor plus 500 basis points per annum. Europi intends to list the Green Bonds on the sustainable bond list of Nasdaq Stockholm within 12 months and Nasdaq Transfer Market within 60 days, with an ambition to have the Green Bonds admitted to trading within 30 days.
An amount corresponding to the net proceeds from the Green Bonds will be used in accordance with the Company’s green finance framework (the “Green Finance Framework“).
Skandinaviska Enskilda Banken AB (publ) and ABG Sundal Collier AB have acted as advisors in relation to the issue of the Green Bonds. Vinge has acted as legal counsel in relation to the issue of the Green Bonds.
More information regarding the Green Finance Framework and Sustainalytics’ second party opinion can be found at https://europi.se/bond-investors/
For further information, please contact:
Jonathan Willén, CEO, [email protected]
+46 (0) 8 411 55 77
About Europi (www.europi.se)
Europi Property Group, founded in 2019, is a pan-European real estate investment company headquartered in Stockholm (with an office also in London) investing discretionary capital across all sectors with a flexible investment strategy. Europi has since inception completed public and private transactions of more than €700m in gross asset value alongside its established network of local operating partners and completed four successful exists. By combining a truly entrepreneurial, active ownership approach with focus on social and environmental sustainability, Europi generates long term value and positive impact for all stakeholders.
This information was brought to you by Cision http://news.cision.com
View original content:https://www.prnewswire.co.uk/news-releases/europi-property-group-ab-publ-successfully-issues-senior-unsecured-green-bonds-302318389.html
-
Fintech PR7 days ago
Alkira Ranked 25th Fastest-Growing Company in North America and 6th in the Bay Area on the 2024 Deloitte Technology Fast 500™
-
Fintech2 days ago
Fintech Pulse: A Daily Dive into Industry Innovations and Developments
-
Fintech PR7 days ago
Corinex Ranked Number 331 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
-
Fintech PR7 days ago
Cathay Financial Holdings Advances Climate Finance Leadership at COP29, Championing Public-Private Partnerships and Asia’s Low-Carbon Transition
-
Fintech PR6 days ago
ROYAL CANADIAN MINT REPORTS PROFITS AND PERFORMANCE FOR Q3 2024
-
Fintech PR6 days ago
Redefining Financial Frontiers: Nucleus Software Celebrates 30 Years with Synapse 2024 in Singapore
-
Fintech2 days ago
Former MD of SUI Foundation, Greg Siourounis, Joins xMoney Global as Co-Founder and CEO to build MiCA-Regulated Stablecoin Platform
-
Fintech PR7 days ago
EliTe Solar: Realizing Our Mission and Standing by Our Core Values